Table 4.

Multivariable analysis for 7/8 HLA-MUD HCT vs haploidentical HCT, 2013-2017

Covariate	No.	HR	95% Confidence interval	P
OS
Main effect
Haploidentical HCT	393	Reference
7/8 HLA-MUD HCT	230	1.38	1.08-1.78	.01
Remission status
CR1	418	Reference
CR2+	205	1.82	1.41-2.34	<.001
LFS
Main effect
Haploidentical HCT	381	Reference
7/8 HLA-MUD	227	1.21	0.95-1.54	.12
Remission status
CR1	414	Reference
CR2+	194	1.84	1.46-2.33	<.001
Race/ethnicity
White Hispanic	124	Reference
White non-Hispanic	277	0.95	0.71-1.28	.73
Black	75	1.33	0.92-1.94	.13
Asian	32	0.50	0.25-0.97	.04
Other/not specified	100	0.70	0.48-1.03	.07
Conditioning regimen
MAC-TBI	295	Reference
MAC-chemotherapy	111	1.29	0.94-1.75	.11
RIC/NMA	201	1.46	1.12-1.89	.005
NRM
Main effect
Haploidentical HCT	381	Reference
7/8 HLA-MUD HCT	227	2.13	1.50-3.01	<.001
Donor/recipient CMV serostatus
+/+	287	Reference
+/−	55	0.40	0.18-0.86	.02
−/+	143	0.78	0.51-1.19	.25
−/−	121	0.56	0.34-0.92	.02
Relapse
Main effect
Haploidentical HCT	381	Reference
7/8 HLA-MUD HCT	227	0.81	0.57-1.13	.22
Remission status
CR1	414	Reference
CR2+	194	2.39	1.76-3.25	<.001
Race/ethnicity
White Hispanic	124	Reference
White non-Hispanic	277	0.94	0.64-1.39	.76
Black	75	1.24	0.76-2.02	.38
Asian	32	0.36	0.14-0.93	.03
Other/not specified	100	0.58	0.34-0.99	.05
Conditioning regimen
MAC-TBI	295	Reference
MAC-chemotherapy	111	1.60	1.05-2.44	.03
RIC/NMA	201	2.09	1.49-2.95	<.001
aGVHD, grade 2-4
Main effect
Haploidentical HCT	376	Reference
7/8 HLA-MUD HCT	216	1.33	1.02-1.73	.04
Conditioning regimen
MAC-TBI	288	Reference
MAC-chemotherapy	107	0.68	0.47-0.98	.04
RIC/NMA	196	0.68	0.51-0.92	.01
aGVHD, grade 3-4
Main effect
Haploidentical HCT	376	Reference
7/8 HLA-MUD HCT	216	1.86	1.23-2.80	.003
cGVHD
Main effect
Haploidentical HCT	393	Reference
7/8 HLA-MUD HCT	230	1.72	1.34-2.20	<.001